Bartmann P, Gortner L, Pohlandt F, Jaeger H
Department of Pediatrics, University of Ulm, Fed. Rep. of Germany.
J Perinat Med. 1992;20(3):189-96. doi: 10.1515/jpme.1992.20.3.189.
Endotracheal administration of human or xenogenic surfactant preparations is an effective treatment of the respiratory distress syndrome of preterm infants. The application of large amounts of phospholipids to the lung may result in a significant alteration of the local immune response. We studied the influence of the bovine surfactant preparation SF-RI 1 (Alveofact) on lymphocyte functions in vitro. PHA-induced cell proliferation and immunoglobulin synthesis in the presence of whole surfactant as well as six different defined phospholipids were investigated. A marked concentration-dependent suppression of immunoglobulin production independent of the immunoglobulin isotype and cell proliferation was observed in the range of 5 ng/ml-3 mg/ml of a single phospholipid (or SF-RI 1 respectively). It could be demonstrated that suppression of lymphocyte functions was only due to the phospholipid content of the surfactant preparation. These data indicate that in vivo immune functions may be significantly altered by the administration of exogenous surfactant. This may be particularly important in the presence of primary or secondary pulmonary infections.
气管内给予人源性或异种源性表面活性剂制剂是治疗早产儿呼吸窘迫综合征的一种有效方法。向肺部应用大量磷脂可能会导致局部免疫反应发生显著改变。我们在体外研究了牛表面活性剂制剂SF-RI 1（肺泡表面活性物质）对淋巴细胞功能的影响。研究了在存在全表面活性剂以及六种不同的特定磷脂的情况下，PHA诱导的细胞增殖和免疫球蛋白合成。在单一磷脂（或分别为SF-RI 1）浓度为5 ng/ml - 3 mg/ml的范围内，观察到免疫球蛋白产生受到显著的浓度依赖性抑制，且与免疫球蛋白同种型和细胞增殖无关。可以证明，淋巴细胞功能的抑制仅归因于表面活性剂制剂中的磷脂含量。这些数据表明，外源性表面活性剂的给药可能会显著改变体内免疫功能。在存在原发性或继发性肺部感染的情况下，这可能尤为重要。
